Therapeutic approaches to non-Hodgkin's lymphoma in the elderly patient

被引:1
作者
Ninan, Mary J. [3 ]
Morrison, Vicki A. [1 ,2 ]
机构
[1] Vet Affairs Med Ctr, Hematol Oncol Sect, Minneapolis, MN 55417 USA
[2] Vet Affairs Med Ctr, Infect Dis Sect, Minneapolis, MN USA
[3] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA
关键词
diffuse large-cell lymphoma; elderly; follicular lymphoma; NHL; non-Hodgkin's lymphoma; R-CHOP; rituximab; B-CELL LYMPHOMA; DETUDE-DES-LYMPHOMES; PHASE-II TRIAL; ANTI-CD20; MONOCLONAL-ANTIBODY; CHEMOTHERAPY PLUS RITUXIMAB; RANDOMIZED CONTROLLED-TRIAL; TERM-FOLLOW-UP; LOW-GRADE; CHOP CHEMOTHERAPY; IBRITUMOMAB TIUXETAN;
D O I
10.1586/EHM.09.7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The incidence of non-Hodgkin's lymphoma (NHL) is increasing among all age groups, with a median age at diagnosis of 67 years. With the increase in the geriatric population, there is a need for the development and validation of treatment strategies for NHL for these patients. Therapy in elderly patients is affected by multiple factors, especially comorbidities. Over the past decade, some treatment trials have included older patients. The disease incidence, characteristics and treatment approaches for both follicular and diffuse aggressive NHL histologies in elderly patients are reviewed, as well as the impact of aging on the care of these patients.
引用
收藏
页码:173 / 182
页数:10
相关论文
共 50 条
[21]   Rituximab for the therapy of non-Hodgkin's lymphoma [J].
Rummel, M. J. .
ONKOLOGE, 2007, 13 (03) :227-+
[22]   Bortezomib for the treatment of non-Hodgkin's lymphoma [J].
Bose, Prithviraj ;
Batalo, Michael S. ;
Holkova, Beata ;
Grant, Steven .
EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (16) :2443-2459
[23]   Rituximab in the treatment of non-Hodgkin's lymphoma [J].
Hauptrock, Beate ;
Hess, Georg .
BIOLOGICS-TARGETS & THERAPY, 2008, 2 (04) :619-633
[24]   Antiangiogenic Therapies in Non-Hodgkin's Lymphoma [J].
Ruan, J. .
CURRENT CANCER DRUG TARGETS, 2011, 11 (09) :1030-1043
[25]   Novel antibodies against follicular non-Hodgkin's lymphoma [J].
van Meerten, Tom ;
Hagenbeek, Anton .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2011, 24 (02) :231-256
[26]   CLINICAL UPDATES Non-Hodgkin lymphoma [J].
Al-Naeeb, Anna Bowzyk ;
Ajithkumar, Thankamma ;
Behan, Sarah ;
Hodson, Daniel James .
BMJ-BRITISH MEDICAL JOURNAL, 2018, 362
[27]   The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma [J].
Smolewski, Piotr ;
Robak, Tadeusz .
EXPERT OPINION ON DRUG DISCOVERY, 2015, 10 (07) :791-808
[28]   Radioimmunotherapy in non-Hodgkin lymphoma: Prediction and assessment of response [J].
Eskian, Mahsa ;
Khorasanizadeh, MirHojjat ;
Kraeber-Bodere, Francoise ;
Rezaei, Nima .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 107 :182-189
[29]   Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma [J].
Barth, Matthew J. ;
Chu, Yaya ;
Hanley, Patrick J. ;
Cairo, Mitchell S. .
BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (04) :597-616
[30]   Dosimetric Approaches for Radioimmunotherapy of Non-Hodgkin Lymphoma in Myeloablative Setting [J].
Cicone, Francesco ;
Sarnelli, Anna ;
Guidi, Claretta ;
Belli, Maria Luisa ;
Ferrari, Mahila Esmeralda ;
Wahl, Richard ;
Cremonesi, Marta ;
Paganelli, Giovanni .
SEMINARS IN NUCLEAR MEDICINE, 2022, 52 (02) :191-214